Skip to main content

Does Vyepti cause weight gain?

Medically reviewed by Leigh Ann Anderson, PharmD. Last updated on July 21, 2025.

Official Answer by Drugs.com

No, weight gain was not seen in safety studies of Vyepti lasting up to one year long. In general, Vyepti is well tolerated, with less than 2% of patients dropping out of clinical studies due to side effects. According to the manufacturer, a pharmacokinetic study looking at the effects of age, race, sex, and body weight did not suggest any clinically significant impact due to Vyepti.

Vyepti (eptinezumab-jjmr), a calcitonin gene-related peptide antagonist, was the first FDA-approved IV treatment for migraine prevention in adults.

What side effects do I expect to see with Vyepti?

Safety studies included over 2,000 adult patients receiving either the 100 or 300 mg dose of Vyepti for migraine prevention.

The most common side effects were common cold symptoms like stuffy nose and scratchy throat (6% to 8% of patients taking Vyepti vs. 6% placebo) and allergic (hypersensitivity) reactions (1% to 2% of patients taking Vyepti vs. 0% placebo).

Some allergic reactions, such as anaphylaxis, may be serious. If you have symptoms of an allergic reaction, contact your doctor or get emergency medical care right away. These symptoms can include:

Other side effects may include high blood pressure and Raynaud’s phenomenon.

These are not all of the possible side effects of Vyepti. If you have further questions or concerns about side effects contact your healthcare provider. To learn more, review the section on Side Effects of Vyepti.

How is Vyepti given?

The recommended dose is 100 mg intravenously (IV) given every 3 months. Some patients may benefit from a higher dose of 300 mg. The infusion takes about 30 minutes and is only given by your healthcare provider.

Review How long does it take Vyepti to work? to learn more about how well Vyepti works.

Related questions

How well does Vyepti work to prevent migraine?

In two Phase 3 clinical studies of Vyepti (PROMISE-1 in episodic migraine and PROMISE-2 in chronic migraine), researchers were looking to see how many fewer days of migraine headaches patients had over a 12-week period. At the start of the study, on average, patients had 8.6 migraine days per month.

In the episodic migraine study, the number of mean monthly migraines dropped by 3.9 days for the 100 mg dose and by 4.3 days for the 300 mg dose, compared to 3.2 fewer days in the placebo group.

In the chronic migraine study, the number of mean monthly migraines dropped by 7.7 days for the 100 mg dose and by 8.2 days for the 300 mg dose, compared to 5.6 fewer days in the placebo group.

Vyepti also exhibited a benefit over placebo for both the 100 and 300 mg doses of Vyepti as early as the first day after treatment, according the studies conducted by the manufacturer. The percentage of patients experiencing a migraine was lower for Vyepti than with placebo for most of the first 7 days.

Vyepti is classified as a humanized monoclonal antibody that binds to calcitonin gene-related peptide (CGRP) ligand and blocks its binding to the receptor.

Visit this comprehensive list of CGRP migraine medications to learn more about this class of drug for migraines treatment and prevention.

This is not all the information you need to know about Vyepti (eptinezumab-jjmr) for safe and effective use and does not take the place of your doctor’s directions. Review the full product information and discuss this information and any questions you have with your doctor or other health care provider.

References
  • Ashina M, Saper J, Cady R, et al. Eptinezumab in episodic migraine: A randomized, double-blind, placebo-controlled study (PROMISE-1). Cephalalgia. 2020 Mar;40(3):241-254. doi: 10.1177/0333102420905132
  • Vyepti (eptinezumab-jjmr) prescribing information. Updated 3/2025. Lundbeck. Bothell, WA. Accessed July 21, 2025 at https://www.lundbeck.com/content/dam/lundbeck-com/americas/united-states/products/neurology/vyepti_pi_us_en.pdf
  • Lipton RB, Goadsby PJ, Smith J, et al. Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2. Neurology. 2020 Mar 31;94(13):e1365-e1377. doi: 10.1212/WNL.0000000000009169. Erratum in: Neurology. 2023 Aug 8;101(6):283. doi: 10.1212/WNL.0000000000207168
  • Drug Trials Snapshots: VYEPTI. US Food and Drug Administration (FDA). Accessed July 21, 2025 at https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-vyepti

Read next

How long do Vyepti infusions take?

Vyepti intravenous (IV) infusions take about 30 minutes and are given 4 times per year (every 3 months). You will receive the infusion at your doctor’s office or at a special infusion center, and the total time spent there may be longer than 30 minutes. Continue reading

Is obesity a major risk factor for Covid-19?

Obesity is a major risk factor for covid-19 and people who are obese are more likely than those who are not obese to contract Covid-19 at a younger age, develop severe Covid-19, require hospitalization, oxygen, mechanical ventilation, intubation, or admission into ICU, end up in hospital sooner, or die from Covid-19. Continue reading

What is the natural Mounjaro recipe for weight loss?

The “natural Mounjaro recipe” has exploded in popularity as a viral wellness drink, with social media users touting its potential for weight loss and metabolic health. While the name is inspired by the prescription medication Mounjaro (tirzepatide), it’s important to clarify that this homemade drink is not a substitute for any pharmaceutical therapy. Instead, it reflects a growing interest in natural, do-it-yourself solutions for weight management and overall wellness.

Continue reading

See also:

Related medical questions

Drug information

Related support groups